AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
AIIMS Jammu is a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states
The academy has secured partnerships with 15 esteemed hospitals
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
The initiative aims to empower individuals to take proactive steps towards monitoring their health
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Subscribe To Our Newsletter & Stay Updated